Navigation Links
Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care

oellex, the Company's lead compound, a PRM (progesterone receptor modulator) has recently completed a successful U.S. three-month Phase 2 clinical trial for the treatment of uterine fibroids, a condition that affects numerous women of childbearing age in the United States and results in a significant number of hysterectomies each year. Proellex has recently completed a six-month European Phase 1/2 study for the treatment of endometriosis, a condition that affects approximately 5.5 million women in the United States and Canada. Androxal(TM), the Company's other program in late clinical development, is designed to restore normal testosterone production by the testes in men and has recently completed a six-month U.S. non-pivotal Phase 3 clinical trial for the treatment of testosterone deficiency due to secondary hypogonadism. According to industry sources, approximately 13 million men in the United States experience testosterone deficiency. The Company is planning meetings with the FDA for all three programs to lay out the remaining clinical program pathway required before a New Drug Application may be submitted for each product candidate.

For more information, please visit the Company's website at http://www.reprosrx.com.

Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to have success in the clinical development of its technologies, the timing of enrollment in such clinical studies and the accuracy of such studies, Repros' ability to raise additional capital on acceptable terms or at all, and such other risks which are identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, and Repros' Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, as they may be updated by the Company's Exchange Act filings from time to time. These documents are available on request from Repros Therapeutics or at
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... made a lot of progress in the past ... now accepted in high-reliability environments, and are even ...
(Date:12/15/2014)... 2014 Research and Markets , ... ) has announced the addition of the "Cardiac ... to their offering. Global Guidewires sector is projected ... North America accounts for nearly 35% (2015) ... claims approximately 25% (2018). Asia-Pacific ...
(Date:12/15/2014)... 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... to the NASDAQ Biotechnology Index (NBI). The addition ... upon market open on December 22, 2014. ... track the performance of a set of NASDAQ-listed ... pharmaceutical according to the Industry Classification Benchmark. The ...
Breaking Medicine Technology:MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
(Date:12/19/2014)... Slone Partners , a national recruitment firm ... and laboratory testing industries, has promoted Leslie Loveless ... announcement comes after a year of expansion by ... Boston and several new additions to the team. ... experience," said Adam Slone, Chief Executive Officer. “Diagnostics ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Being in good shape ... report. They looked at data from more than 57,000 ... underwent treadmill tests between 1991 and 2009. Those in ... of having high blood pressure at the start of the ... high levels of fitness. Of the more than 8,000 ...
(Date:12/19/2014)... (HealthDay News) -- Traveling through the same U.S. airport ... three others within a four-hour time span, illustrating just ... shows. "The exposures in this report were not ... international terminal, highlighting the fact that measles is highly ... infectious disease specialist at the U.S. Centers for Disease ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
(Date:12/17/2014)... Miami, FL (PRWEB) December 17, 2014 ... has not been able to eradicate the head louse ... and hassle for parents. Each year between six and ... Lice Troopers, the Miami-based lice removal treatment company comes ... safe, non-toxic and environmentally friendly. With its track record ...
Breaking Medicine News(10 mins):Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... Sichuan University in Chengdu, China, investigated eye movements in Chinese ... that control them and how they compare between different human ... that is rare in British people, is much more common ... in brain function between different populations. Tests ...
... Reporter , WEDNESDAY, March 23 (HealthDay News) -- Though ... babies, Americans, level of exposure to mercury from sources ... risk of heart disease, stroke or other cardiovascular disease, ... research that produced inconsistent results, scientists from Harvard School ...
... survey of over 9,000 people in seven different countries across Europe ... of life in the time they had left, rather than extend ... illnesses such as cancer, and issues raised when caring for a ... The research was carried out as part of an EU-funded project ...
... By Serena Gordon HealthDay Reporter , WEDNESDAY, ... the diabetes drug Actos helped people who had prediabetes ... extremely effective in preventing diabetes," said study author Dr. ... and chief of the diabetes division at the University ...
... Boston (March 23, 2011) A paper, "Association of ... Cardiac Events," published in the March 23/30 issue of ... research done by Tufts Clinical and Translational Science ... Issa J. Dahabreh, MD. This paper was also developed ...
... March 23 (HealthDay News) -- The risk of lung cancer ... that of those who prefer regular cigarettes, researchers report. ... Administration advisory panel that made headlines Friday when it said ... While the panel concluded that menthols, minty flavor seems to ...
Cached Medicine News:Health News:Eye movement differs in British and Chinese populations 2Health News:Americans' Exposure to Mercury From Fish Won't Harm Hearts: Study 2Health News:Americans' Exposure to Mercury From Fish Won't Harm Hearts: Study 3Health News:Europe-wide survey reveals priorities for end-of-life care 2Health News:Europe-wide survey reveals priorities for end-of-life care 3Health News:Actos Cut Risk of Prediabetes Becoming Diabetes in Study 2Health News:Actos Cut Risk of Prediabetes Becoming Diabetes in Study 3Health News:Tufts paper assesses effect of episodic sexual/physical activity on cardiac events 2Health News:Tufts paper assesses effect of episodic sexual/physical activity on cardiac events 3Health News:Menthol Cigarettes Pose No Added Lung Cancer Risk: Study 2
... is one of the world's ... with a 7 F introducer, ... is designed to lower the ... allow introduction in smaller, more ...
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... Guidant Flextend lead is ... lead with an extendable/retractable ... helix design offers various ... permanent implantation in the ...
... is a low profile implantable bipolar ... stimulation of either the atrium or ... supplied with a screwdriver shape stylet ... lead. The ring tip and fixation ...
Medicine Products: